Publication|Articles|November 14, 2025
Supplements and Featured Publications
- Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Advertisement
This clinical brief is supported by Celltrion Inc.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
3
In CLL, New Therapies Offer Potential for Personalized Approaches
4
ICYMI: Highlights From CROI 2025
5





































